409 related articles for article (PubMed ID: 27152635)
41. Clinical and economic burden of breakthrough seizures.
Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
[TBL] [Abstract][Full Text] [Related]
42. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
DaCosta Byfield S; Nash Smyth E; Mytelka D; Bowman L; Teitelbaum A
J Med Econ; 2013 Dec; 16(12):1379-86. PubMed ID: 24074258
[TBL] [Abstract][Full Text] [Related]
43. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
44. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
Yeaw J; Lee WC; Aagren M; Christensen T
J Manag Care Pharm; 2012; 18(1):21-32. PubMed ID: 22235952
[TBL] [Abstract][Full Text] [Related]
45. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
Croteau SE; Cook K; Sheikh L; Chawla A; Sammon J; Solari P; Kim B; Hinds D; Thornburg CD
J Manag Care Spec Pharm; 2021 Mar; 27(3):316-326. PubMed ID: 33645244
[No Abstract] [Full Text] [Related]
46. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
47. The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States.
Rice JB; White AG; Galebach P; Korenblat KM; Wagh A; Lovelace B; Wan GJ; Jamil K
Curr Med Res Opin; 2017 Aug; 33(8):1473-1480. PubMed ID: 28509578
[TBL] [Abstract][Full Text] [Related]
48. Health care resource utilization and medical costs of spinal cord injury with neuropathic pain in a commercially insured population in the United States.
Margolis JM; Juneau P; Sadosky A; Cappelleri JC; Bryce TN; Nieshoff EC
Arch Phys Med Rehabil; 2014 Dec; 95(12):2279-87. PubMed ID: 25159715
[TBL] [Abstract][Full Text] [Related]
49. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
50. Wilson's Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States.
Rustgi VK; Gupta K; Tait C; Bhurwal A; Kabaria S; Catalano C; Li Y; Minacapelli CD
Hepatol Commun; 2022 Feb; 6(2):389-398. PubMed ID: 34559472
[TBL] [Abstract][Full Text] [Related]
51. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
Lu M; Oladapo A; Wu Y; Farahbakhshian S; Ewenstein B
J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
[No Abstract] [Full Text] [Related]
52. Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database.
Zhao Z; Zhu Y; Fang Y; Ye W; McCollam P
J Med Econ; 2015; 18(9):655-65. PubMed ID: 25891183
[TBL] [Abstract][Full Text] [Related]
53. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia.
Carroll B; Irwin DE
J Manag Care Spec Pharm; 2019 Jul; 25(7):810-816. PubMed ID: 31232207
[TBL] [Abstract][Full Text] [Related]
54. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of healthcare costs and utilization for patients with gout: a population-based matched cohort study.
Lee YY; Tang CH; Chen JH; Kuo LN; Ko Y
Curr Med Res Opin; 2018 Apr; 34(4):735-740. PubMed ID: 29243513
[TBL] [Abstract][Full Text] [Related]
56. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings.
Black J; Reaven NL; Funk SE; McGaughey K; Ohayon M; Guilleminault C; Ruoff C; Mignot E
Sleep Med; 2014 May; 15(5):522-9. PubMed ID: 24768358
[TBL] [Abstract][Full Text] [Related]
57. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
[TBL] [Abstract][Full Text] [Related]
58. Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Bonafede M; Jing Y; Gdovin Bergeson J; Liffmann D; Makenbaeva D; Graham J; Deitelzweig SB
Hosp Pract (1995); 2011 Aug; 39(3):16-22. PubMed ID: 21881388
[TBL] [Abstract][Full Text] [Related]
59. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data.
Strand V; Shah R; Atzinger C; Zhou J; Clewell J; Ganguli A; Tundia N
Curr Med Res Opin; 2020 Jan; 36(1):161-168. PubMed ID: 31433680
[No Abstract] [Full Text] [Related]
60. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
